At present, more accurate prognostic markers than traditional factors such as tumor size, nodal status and estrogen receptor status are being investigated that could identify high-risk groups and that could better address treatment efforts those
breast
cancer patients.
The nuclear phosphoprotein p53 is expressed in all normal cells and appears to function in cell cycle regulation. In breast carcinoma expression of p53 protein is associated with mutations of p53 gene. These altered genes encode mutant-type p53
proteins
that can be detected by immunohistochemical techniques unable to detect rapidly degraded wild-type protein.
In this retrospective study we investigated the correlation between p53 protein expression and age, menopausal status, size of tumor, nodal status, clinical stage and estrogen receptor status, and its relation to overall survival and disease-free
interval of breast cancer in Korea by immumnohistochemical analysis using polyclonal antibody.
@ES The results were as follows:
@EN 1) Thirteen out of 43(30.2%) breast cancer patients were p53 protein positive.
2) It seemed to have increasing tendency of p53 protein expression according to nodal involvement and clinical stage. But stastistically not singnificant.
3) p53 protein positive cancers were worse than negative cancers in 5 year survival rate(16.7±0.11% vs. 86.4±0.06%) and disease-free interval(37.6±6.95 months vs. 63.4±4.23 months).
These results suggested that mutant p53 protein, as detected by immunohistochemistry in paraffin embedded tumor tissue, appears to influence 5 year survival and disease-free interval in patients with breast cancer.
|